TAK — Takeda Pharmaceutical Share News
0.000.00%
Last trade - 00:00- $66.14bn
- $92.15bn
- ¥5tn
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Nimbus, Lilly sign deal to develop new oral obesity drug
Takeda's AI-crafted psoriasis pill succeeds in late-stage studies (updated)
Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
Zasocitinib Landmark Ph3 Plaque Psoriasis Data Show Promise To Deliver Clear Skin
Brief: Takeda Canada British Columbia Reimburses Fruzaqlatm
Brief: Takeda Pharmaceutical Conducted Thorough Assessment, Found There Was No Confirmed Causal Relationship To Use Of Adzynma &Patient Death - Spokesperson
US FDA investigates Takeda's blood disorder drug after pediatric death (updated)
US FDA investigates death tied to Takeda's blood disorder drug
Brief: FDA Investigates Death Linked to Adzynma Treatment for Congenital Thrombotic Thrombocytopenic Purpura
Brief: Beacon Biosignals Raises $86 Million to Accelerate AI-Driven Insights into Brain Health
US FDA awards six more fast-track vouchers to speed drug reviews (updated)
US FDA awards six more fast-track vouchers to speed drug reviews (updated)
Table: Takeda Pharma 6-MTH group results (IFRS)
Brief: HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
China's Innovent signs cancer therapy deal with Japan's Takeda (updated)
China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda
Brief: Nabla Bio Signs Second Takeda Collaboration To Advance Ai-Driven Design Of Protein Therapeutics
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership